Gep5 model for multiple myeloma

A method of prognosing a subject suspected of having multiple myeloma or has multiple myeloma, comprising:

• (a) obtaining a biological sample from a subject;
• (b) extracting nucleic acids from the sample to generate an isolated nucleic acid sample;
• and
• (c) measuring gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) by contacting the isolated nucleic acid sample with detectably labeled nucleic acid probes that hybridize to each gene and detecting the complex formed between each gene and probe, wherein an elevated mean, log-normalized gene expression level of at least two of ENO1, FABP5, TRIP13, TAGLN2, and RFC4 as compared to a suitable control for each gene is associated with a poor multiple myeloma prognosis for the subject.

A method of detecting a gene expression profile, comprising:

• (a) contacting a biological sample obtained from a subject with detectably labeled nucleic acid probes that hybridize to each of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4);
• and
• (b) measuring gene expression levels of ENO1, FABP5, TRIP13, TAGLN2, and RFC4;
• and
• (c) detecting a gene expression profile by determining a mean, log-normalized gene expression level of at least two of ENO1, FABP5, TRIP13, TAGLN2, and RFC4.